Here is the new miracle weight loss product: it promises greater weight loss than ever before.
According to a statement by the Eli Lilly pharmaceutical company on Thursday, two further Phase III clinical trials have also yielded positive results for the experimental obesity treatment, retatrutide, and the company plans to submit an application for market authorization to the U.S. Food and Drug Administration (FDA) in the first quarter of 2026.
According to a statement by the Eli Lilly pharmaceutical company on Thursday, two further Phase III clinical trials have also yielded positive results for the experimental obesity drug, retatrutide, and the company plans to submit an application for market authorization to the US Food and Drug Administration (FDA) in the first quarter of 2026.
